npr glp 1 GLP-1s like Ozempic transformed weight loss and diabetes. Is addiction next? : A new NPR article features

The cardiovascular safety profile of GLP-1 agents is well-established from SUSTAIN and REWIND trials, which documented reduced cardiac events in patients with type 2 diabetes

We next investigated whether intracellular oxidation of l-valine followed by closure of K ATP -channels might be causing the depolarization

tirzepatide, which adds a second gut hormone, is sold as Mounjaro and Zepbound

No direct pharmacokinetic interaction exists between semaglutide and topiramate as they are metabolised through different pathways

This framing distinguishes the product from pharmaceutical GLP-1 drugs and aligns it more closely with the supplement market's holistic approach

Its not the drug so much as the speed of the change, in an anatomically susceptible person